GlassScriptPhysician profile
Satyajit Daniel
NPI 1770564999
$6,250.42
in general payments reported to CMS, 2019-2025
31 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $230 · 2021: $307 · 2022: $818 · 2023: $1,304 · 2024: $1,188 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,385 · Education: $265 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.80 |
| Education | $265.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.22 | 2019-2025 | Rinvoq, Linzess, Mavyret |
| Janssen Biotech, INC. | $980.90 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $874.36 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $731.89 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $671.04 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $518.78 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Allergan, INC. | $168.22 | 2019-2020 | |
| Pfizer INC. | $146.63 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $145.50 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $110.82 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $77.65 | 2024-2025 | Zenpep, Vowst |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Ipsen Biopharmaceuticals, INC | $66.70 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $61.81 | 2021-2022 | |
| Lilly USA, LLC | $59.81 | 2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.61 | 2019 | |
| Ferring Pharmaceuticals INC. | $51.82 | 2021-2024 | Clenpiq |
| Intercept Pharmaceuticals, INC. | $46.36 | 2020-2024 | |
| Qol Medical, LLC | $32.99 | 2019-2023 | Sucraid |
| Amgen INC. | $32.43 | 2023-2025 | Amjevita, Avsola |
| Genzyme Corporation | $22.75 | 2025 | |
| Phathom Pharmaceuticals, INC. | $22.57 | 2025 | Voquezna |
| Ardelyx, INC. | $20.42 | 2024 | Ibsrela |
| Braintree Laboratories, INC. | $19.15 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.04 | 2023 | |
| Organon LLC | $17.79 | 2023 | Renflexis |
| Fresenius Kabi USA, LLC | $16.64 | 2023 | |
| Mallinckrodt Hospital Products INC. | $15.14 | 2023 | Terlivaz |
| Cook Medical LLC | $14.46 | 2022 | |
| Shionogi INC | $12.00 | 2019 | |
| Shire North American Group INC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satyajit Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.